FINWIRES · TerminalLIVE
FINWIRES

Voyager Technologies to Gain From Astrobotic Deal, NASA Moon Work, Wedbush Says

By

Voyager Technologies (VOYG) could be better placed for future moon-related contracts after its planned Astrobotic acquisition, with more NASA exposure, possible earnings gains in 2027, and faster growth as lunar activity increases later this decade, Wedbush said in a note Tuesday.

Voyager agreed to buy Astrobotic Technology for about $300 million, including contingent payments, in a cash-and-stock deal expected to close in fiscal Q3, which adds landers, rovers, power systems, precision landing technology, and other tools that should help Voyager expand its lunar strategy, Wedbush said.

Astrobotic's ties with the National Aeronautics and Space Administration, Defense Advanced Research Projects Agency, Astrolab, and other space and national security groups could help Voyager compete for more future work as NASA is expected to award more than a dozen landing missions in 2026 and support 73 lunar landings by 2032, creating more chances for Voyager to win business, according to the note.

Wedbush added that the deal should widen Voyager's addressable market in lunar programs and complement its Max Space investment in expandable space habitats.

Wedbush kept its outperform rating for Voyager and maintained its $60 price target.

Price: $49.75, Change: $+2.26, Percent Change: +4.76%

Related Articles

Wire

Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis

Karyopharm Therapeutics (KPTI) said Tuesday that a late-breaking abstract from its phase 3 trial of selinexor combined with ruxolitinib in myelofibrosis was accepted for an oral presentation at the 2026 European Hematology Association Congress in mid-June.The company said new data will highlight a post-hoc analysis of 24 patients from phase 1 of the trial, which indicates that achieving a spleen volume reduction of 35% or more may predict overall survival, consistent with a similar analysis from the phase 3 trial.Shares of Karyopharm Therapeutics were down more than 8% in Tuesday trading.Price: $8.99, Change: $-0.84, Percent Change: -8.50%

$KPTI
Wire

Mastercard Appoints Ling Hai as CFO; Sachin Mehra to Become Chief Business Officer

Mastercard (MA) said Tuesday it has appointed Ling Hai, president of Asia Pacific, Europe, Middle East and Africa, as the company's chief financial officer, effective Aug. 3.He succeeds Sachin Mehra, who will move into a newly created role as chief business officer, responsible for country operations across the globe, Mastercard said.Additionally, President of the Americas Linda Kirkpatrick will become chief services officer, succeeding Craig Vosburg, the firm said, adding that Vosburg will transition to vice chair and serve as a global ambassador for the company.Dimi Dosis, president of Eastern Europe, Middle East and Africa, will become chief commercial payments officer, succeeding Raj Seshadri, who will become a senior strategic advisor to the chief executive officer, Mastercard said.Price: $483.78, Change: $-11.47, Percent Change: -2.32%

$MA
Wire

Life Time Seen Benefiting From High-Income Exposure, RBC Says

Life Time Group (LTH) is well positioned to benefit from its high income member base and room to expand wallet share through in-center services, RBC Capital Markets said in a Tuesday note.Investor interest centered on in-center growth, new club growth, balance sheet leverage and capital allocation, according to the note.RBC said Life Time's median household income rose to $160,000 in 2025 from $119,000 in 2021, supporting what it sees as a favorable backdrop for spending across the membership base.However, RBC analysts said the biggest growth opportunity remains growing wallet share from existing users of in-center services, especially dynamic personal training, which it said accounts for about half of in-center revenue.The research firm also noted new club productivity is improving, with some locations reaching maturity at 24 months, faster than the historical average and site selection becoming more efficient.RBC maintained its outperform rating on Life Time and raised its price target to $43 from $38.Price: $32.33, Change: $+0.99, Percent Change: +3.16%

$LTH